Revolutionizing Cancer Research with CertisOI Assistant™ Launch
Certis Oncology Solutions, a leader in translational science and emerging technology, has introduced the CertisOI Assistant™, an innovative chatbot staying at the forefront of preclinical oncology research. This advanced tool leverages artificial intelligence and machine learning, utilizing OpenAI’s ChatGPT language model to provide researchers with key insights and data regarding cancer models and drug response. This innovation aims to aid in early drug development decisions with greater precision and efficiency.
Enhancing Research Efficiency
The CertisOI Assistant serves as a natural language interface for accessing vast amounts of genomic and drug sensitivity data from numerous cancer research models. This includes their unique patient-derived xenograft (PDX) models and publicly available cancer cell lines sourced from established databases. By leveraging the company’s proprietary CertisAI Predictive Oncology Intelligence™, the assistant stands out as a unique platform that identifies complex gene expression signatures correlating with drug response. This allows researchers to use a data-driven approach in selecting models and defining biomarker strategies without the usual complexities associated with traditional research methods.
Features of the CertisOI Assistant
One of the standout features of the CertisOI Assistant is its capability to convert query results into various visual formats such as charts and graphs. This feature enables researchers to download both summary and detailed data, facilitating easy sharing among peers and collaborators. The assistant's design encourages an intuitive user experience, speeding up data retrieval and analysis significantly.
Supporting Precision Cancer Medicine
Peter Ellman, President and CEO of Certis Oncology, has emphasized that the introduction of the CertisOI Assistant is a significant advancement towards realizing individualized medicine for cancer patients. By providing researchers with rapid analytical tools to interpret data, the assistant is expected to shorten the time needed for scientific investigations and ultimately support the development of more targeted and effective cancer treatments.
Access and Availability
The CertisOI Assistant is currently available for free to cancer researchers globally, enhancing accessibility to vital resources that can drive oncology research forward. This accessibility is pivotal in democratizing research tools in the fight against cancer, making it particularly valuable given the collaborative nature of modern scientific inquiry.
About CertisAI™
CertisAI™ represents a pioneering predictive platform that Certis Oncology Solutions has developed particularly for cancer research purposes. It is recognized as the first validated AI/ML platform commercially available that accurately predicts therapeutic responses by analyzing complex gene signatures. This groundbreaking tool empowers pharmaceutical researchers and clinicians to better identify treatment options tailored to the unique gene expressions found in specific tumors.
About Certis Oncology Solutions
Founded in 2016, Certis Oncology Solutions is committed to bridging the gap in precision oncology. Its Oncology Intelligence® provides highly predictive therapeutic response data derived from state-of-the-art cancer models. By partnering with physician-scientists and industry researchers, the company works to enhance access to precision oncology and improve the translational efficacy between preclinical findings and clinical applications. Certis's approach includes personalized functional testing to inform and optimize individual cancer treatment strategies.
Equipped with a CLIA-certified and AAALAC-accredited laboratory in San Diego, Certis is strategically positioned in a thriving life sciences hub, which facilitates cutting-edge research and innovation.
Frequently Asked Questions
What is the CertisOI Assistant™?
The CertisOI Assistant is an AI-driven chatbot tool designed to assist cancer researchers by providing insights on cancer models and drug responses.
What benefits does the CertisOI Assistant offer researchers?
This tool allows for quick access to comprehensive drug sensitivity data and helps to turn research queries into actionable insights efficiently.
Is the CertisOI Assistant available for all researchers?
Yes, the CertisOI Assistant is available for free to cancer researchers around the world.
How does CertisAI™ enhance cancer treatment development?
CertisAI™ predicts therapeutic efficacy by identifying complex gene expression signatures, which aids in the development of personalized treatment options.
What is the mission of Certis Oncology Solutions?
Certis Oncology Solutions aims to advance precision oncology by providing cutting-edge predictive tools and facilitating collaborations in cancer research.
